651 related articles for article (PubMed ID: 18728033)
21. Ex vivo induction and expansion of antigen-specific cytotoxic T cells by HLA-Ig-coated artificial antigen-presenting cells.
Oelke M; Maus MV; Didiano D; June CH; Mackensen A; Schneck JP
Nat Med; 2003 May; 9(5):619-24. PubMed ID: 12704385
[TBL] [Abstract][Full Text] [Related]
22. Tetanus toxoid provides efficient T-cell help for the induction of HA-1(H) cytotoxic T cells.
Eiz-Vesper B; Horn PA; Daubert C; Khattab B; Blasczyk R
Transfusion; 2006 Jul; 46(7):1210-20. PubMed ID: 16836569
[TBL] [Abstract][Full Text] [Related]
23. Ex vivo expansion protocol for human tumor specific T cells for adoptive T cell therapy.
Rasmussen AM; Borelli G; Hoel HJ; Lislerud K; Gaudernack G; Kvalheim G; Aarvak T
J Immunol Methods; 2010 Apr; 355(1-2):52-60. PubMed ID: 20171968
[TBL] [Abstract][Full Text] [Related]
24. Enhancement of T cell activation by immobilized hu5C8 (anti-CD40L) monoclonal antibody.
Arpinati M; Chirumbolo G; Rondelli D
Eur J Haematol; 2008 Apr; 80(4):322-30. PubMed ID: 18081708
[TBL] [Abstract][Full Text] [Related]
25. Induction of tumor antigen-specific cytotoxic T cell responses in naïve mice by latex microspheres-based artificial antigen-presenting cell constructs.
Shen C; Zhang J; Xia L; Meng F; Xie W
Cell Immunol; 2007 May; 247(1):28-35. PubMed ID: 17720150
[TBL] [Abstract][Full Text] [Related]
26. The frequency of regulatory CD3+CD8+CD28- CD25+ T lymphocytes in human peripheral blood increases with age.
Simone R; Zicca A; Saverino D
J Leukoc Biol; 2008 Dec; 84(6):1454-61. PubMed ID: 18780874
[TBL] [Abstract][Full Text] [Related]
27. A new model of trispecific antibody resulting the cytotoxicity directed against tumor cells.
Song LP; Cheng JL; Wang XB; Zhang Z; Fang M; Zhou ZY; Huang HL
Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao (Shanghai); 2003 Jun; 35(6):503-10. PubMed ID: 12796809
[TBL] [Abstract][Full Text] [Related]
28. GMP production of anti-tumor cytotoxic T-cell lines for adoptive T-cell therapy in patients with solid neoplasia.
Turin I; Pedrazzoli P; Tullio C; Montini E; La Grotteria MC; Schiavo R; Perotti C; Locatelli F; Carretto E; Maccario R; Siena S; Montagna D
Cytotherapy; 2007; 9(5):499-507. PubMed ID: 17786611
[TBL] [Abstract][Full Text] [Related]
29. In vivo persistence of genetically modified T cells generated ex vivo using the fibronectin CH296 stimulation method.
Yu SS; Nukaya I; Enoki T; Chatani E; Kato A; Goto Y; Dan K; Sasaki M; Tomita K; Tanabe M; Chono H; Mineno J; Kato I
Cancer Gene Ther; 2008 Aug; 15(8):508-16. PubMed ID: 18464805
[TBL] [Abstract][Full Text] [Related]
30. Adoptive transfer of pTRP2-specific CTLs expanding by bead-based artificial antigen-presenting cells mediates anti-melanoma response.
Lu X; Jiang X; Liu R; Zhao H; Liang Z
Cancer Lett; 2008 Nov; 271(1):129-39. PubMed ID: 18621475
[TBL] [Abstract][Full Text] [Related]
31. Artificial antigen-presenting cells: artificial solutions for real diseases.
Oelke M; Krueger C; Giuntoli RL; Schneck JP
Trends Mol Med; 2005 Sep; 11(9):412-20. PubMed ID: 16103011
[TBL] [Abstract][Full Text] [Related]
32. Targeting of T cells to CEA-expressing tumor cells by chimeric immune receptors with a highly specific single-chain anti-CEA activity.
Arakawa F; Shibaguchi H; Xu Z; Kuroki M
Anticancer Res; 2002; 22(6C):4285-9. PubMed ID: 12553071
[TBL] [Abstract][Full Text] [Related]
33. Bispecific antibodies increase T-cell stimulatory capacity in vitro of human autologous virus-modified tumor vaccine.
Haas C; Strauss G; Moldenhauer G; Iorio RM; Schirrmacher V
Clin Cancer Res; 1998 Mar; 4(3):721-30. PubMed ID: 9533542
[TBL] [Abstract][Full Text] [Related]
34. CD28 costimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and antitumor efficacy of adoptively transferred T cells.
Kowolik CM; Topp MS; Gonzalez S; Pfeiffer T; Olivares S; Gonzalez N; Smith DD; Forman SJ; Jensen MC; Cooper LJ
Cancer Res; 2006 Nov; 66(22):10995-1004. PubMed ID: 17108138
[TBL] [Abstract][Full Text] [Related]
35. Murine CD8 lymphocyte expansion in vitro by artificial antigen-presenting cells expressing CD137L (4-1BBL) is superior to CD28, and CD137L expressed on neuroblastoma expands CD8 tumour-reactive effector cells in vivo.
Yan X; Johnson BD; Orentas RJ
Immunology; 2004 May; 112(1):105-16. PubMed ID: 15096190
[TBL] [Abstract][Full Text] [Related]
36. CD3 x CD28 cross-interacting bispecific antibodies improve tumor cell dependent T-cell activation.
Willems A; Schoonooghe S; Eeckhout D; De Jaeger G; Grooten J; Mertens N
Cancer Immunol Immunother; 2005 Nov; 54(11):1059-71. PubMed ID: 15891885
[TBL] [Abstract][Full Text] [Related]
37. An optimized method for the functional analysis of human regulatory T cells.
Oberg HH; Wesch D; Lenke J; Kabelitz D
Scand J Immunol; 2006 Sep; 64(3):353-60. PubMed ID: 16918705
[TBL] [Abstract][Full Text] [Related]
38. Identification of HLA-unrestricted CD8+/CD28- cytotoxic T-cell clones specific for leukemic blasts in children with acute leukemia.
Montagna D; Aricò M; Montini E; De Benedetti F; Maccario R
Cancer Res; 1995 Sep; 55(17):3835-9. PubMed ID: 7641201
[TBL] [Abstract][Full Text] [Related]
39. Ex vivo expanded umbilical cord blood T cells maintain naive phenotype and TCR diversity.
Parmar S; Robinson SN; Komanduri K; St John L; Decker W; Xing D; Yang H; McMannis J; Champlin R; de Lima M; Molldrem J; Rieber A; Bonyhadi M; Berenson R; Shpall EJ
Cytotherapy; 2006; 8(2):149-57. PubMed ID: 16698688
[TBL] [Abstract][Full Text] [Related]
40. The requirements for activation of an antigen specific T-cell clone via the CD3 complex.
Colaco CA; Lamb JR
Cell Mol Biol (Noisy-le-grand); 1992 Dec; 38(8):861-6. PubMed ID: 1477602
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
